Switch‐over from Pharmalgen to Alutard Bee and Wasp venom in the UK-Reference-Cited by-同舟云学术

Switch‐over from Pharmalgen to Alutard Bee and Wasp venom in the UK

Published:2019-12 Issue:12 Volume:49 Page:1645-1646
ISSN:0954-7894
Container-title:Clinical & Experimental Allergy
language:en
Short-container-title:Clin Exp Allergy

Author:

Nasser Shuaib¹^ORCID,Whyte Andrew F.²,Durham Stephen R.³,Krishna Mamidipudi Thirumala⁴^ORCID

Affiliation:

1. Department of Allergy Cambridge University Hospitals NHS Foundation Trust Cambridge UK

2. Department of Allergy and Immunology University Hospitals Plymouth NHS Trust Plymouth UK

3. Allergy and Clinical Immunology National Heart and Lung Institute Imperial College London London UK

4. University Hospitals Birmingham NHS Foundation Trust Institute of Immunology and Immunotherapy University of Birmingham Birmingham UK

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cea.13529

Reference8 articles.

1. National Institute for Health and Care Excellence Technology Appraisal Guidance TA246: Pharmalgen for the treatment of bee and wasp venom allergy 2012.https://www.nice.org.uk/guidance/TA246. Accessed October 7 2019.

2. Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines

3. A safe and efficient 7‐week immunotherapy protocol with aluminum hydroxide adsorbed vespid venom

4. Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations

5. Safety of hymenoptera venom immunotherapy: a systematic review

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allergen Immunotherapy Extract Shortages and Their Effects on Clinical Care: A Work Group Report of the AAAAI Immunotherapy, Allergen Standardization, and Allergy Diagnostics Committee;The Journal of Allergy and Clinical Immunology: In Practice;2022-02

2. Developments allergy in 2019 through the eyes of Clinical and Experimental Allergy, Part II clinical allergy;Clinical & Experimental Allergy;2020-12

3. Further considerations for venom immunotherapy following the withdrawal of Pharmalgen;Clinical & Experimental Allergy;2020-07-13